Online inquiry

IVTScrip™ mRNA-Human ARL4C, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WK23242MR)

This product GTTS-WK23242MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the ARL4C protein. This product can be used in Effector CD8+ memory T (Tem) cell-related researches.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Human
RefSeq NM_001282431.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 10123
UniProt ID P56559
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human ARL4C, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WK23242MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK25968MR IVTScrip™ mRNA-Human ARPC3, (Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ARPC3
GTTS-WK26804MR IVTScrip™ mRNA-Human ARHGDIA, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ARHGDIA
GTTS-WK25677MR IVTScrip™ mRNA-Human ARRDC1, (Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ARRDC1
GTTS-WK22022MR IVTScrip™ mRNA-Human ARHGEF7, (Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ARHGEF7
GTTS-WK12242MR IVTScrip™ mRNA-Human ADGRG3, (Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ADGRG3
GTTS-WK17427MR IVTScrip™ mRNA-Human AHSA2, (Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AHSA2
GTTS-WK11940MR IVTScrip™ mRNA-Human ADGRF5, (Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ADGRF5
GTTS-WK25708MR IVTScrip™ mRNA-Human ASF1A, (Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ASF1A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW